SK Chemicals Co Ltd (SK Chemicals), a subsidiary of SK Inc, is primarily engaged in the manufacturing and selling of eco-friendly materials and pharmaceutical products. As of December 2025, SK Chemicals owns and operates three domestic production plants in Ulsan, Cheongju, and Andong, and two manufacturing plants in Yantai and Shantou, China. The company operates local corporations and regional offices in China, the US, Germany, Japan, and Malaysia.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

SK Chemicals’ research and development (R&D) efforts were primarily focused on expanding its vaccine pipeline and enhancing its global presence in the vaccine industry. SK Bioscience, a subsidiary, has been actively involved in the development and commercialization of various vaccines, leveraging its extensive experience in the field. The company has been working on next-generation vaccines, including pneumococcal and cervical cancer vaccines, to broaden its vaccine product portfolio. It has also been collaborating with global multinational companies, international organizations, and biotech firms to establish a robust global vaccine network. The company has utilized its accumulated vaccine development experience and technology to develop a COVID-19 vaccine, which has received funding from organizations such as the Global Fund and CEPI. The vaccine, named SKYCovione, has undergone global Phase 3 clinical trials in regions including Europe and Southeast Asia, and has received approvals from regulatory bodies like the UK's MHRA and WHO's EUL. SK Chemicals has been proactive in securing patents related to its vaccine and pharmaceutical developments. As of December 2025, the company registered a total of 1,282 domestic and 2,107 international patents. These patents cover a range of innovations, including influenza and pneumococcal vaccines. The company's R&D infrastructure is set to expand with the construction of a new global Research & Process Development (R&PD) center, which will focus on basic research, process development, and production in the vaccine and bio sectors. In FY2025, the company incurred expenses of KRW48,500.4 million on R&D, which as a percentage of revenue, stood at 2.1%.